Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID.
Garcia-Perez L, van Eggermond M, van Roon L, Vloemans SA, Cordes M, Schambach A, Rothe M, Berghuis D, Lagresle-Peyrou C, Cavazzana M, Zhang F, Thrasher AJ, Salvatori D, Meij P, Villa A, Van Dongen JJM, Zwaginga JJ, van der Burg M, Gaspar HB, Lankester A, Staal FJT, Pike-Overzet K. Garcia-Perez L, et al. Among authors: zwaginga jj. Mol Ther Methods Clin Dev. 2020 Mar 31;17:666-682. doi: 10.1016/j.omtm.2020.03.016. eCollection 2020 Jun 12. Mol Ther Methods Clin Dev. 2020. PMID: 32322605 Free PMC article.
Successful RAG1-SCID gene therapy depends on the level of RAG1 expression.
Pike-Overzet K, Baum C, Bredius RG, Cavazzana M, Driessen GJ, Fibbe WE, Gaspar HB, Hoeben RC, Lagresle-Peyrou C, Lankester A, Meij P, Schambach A, Thrasher A, Van Dongen JJ, Zwaginga JJ, Staal FJ. Pike-Overzet K, et al. Among authors: zwaginga jj. J Allergy Clin Immunol. 2014 Jul;134(1):242-3. doi: 10.1016/j.jaci.2014.04.033. Epub 2014 Jun 26. J Allergy Clin Immunol. 2014. PMID: 25117803 No abstract available.
Risk Factors, Treatment, and Immune Dysregulation in Autoimmune Cytopenia after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients.
Kruizinga MD, van Tol MJD, Bekker V, Netelenbos T, Smiers FJ, Bresters D, Jansen-Hoogendijk AM, van Ostaijen-Ten Dam MM, Kollen WJW, Zwaginga JJ, Lankester AC, Bredius RGM. Kruizinga MD, et al. Among authors: zwaginga jj. Biol Blood Marrow Transplant. 2018 Apr;24(4):772-778. doi: 10.1016/j.bbmt.2017.12.782. Epub 2017 Dec 19. Biol Blood Marrow Transplant. 2018. PMID: 29277513 Free article. Clinical Trial.
HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P, Jedema I, van Loenen MM, de Boer R, van Egmond HM, Hagedoorn RS, Hoogstaten C, Veld SAJ, Hageman L, van Liempt PAG, Zwaginga JJ, Meij P, Veelken H, Falkenburg JHF, Heemskerk MHM. van Balen P, et al. Among authors: zwaginga jj. Front Immunol. 2020 Aug 20;11:1804. doi: 10.3389/fimmu.2020.01804. eCollection 2020. Front Immunol. 2020. PMID: 32973756 Free PMC article. Clinical Trial.
Stem cell self-renewal: lessons from bone marrow, gut and iPS toward clinical applications.
Staal FJ, Baum C, Cowan C, Dzierzak E, Hacein-Bey-Abina S, Karlsson S, Lapidot T, Lemischka I, Mendez-Ferrer S, Mikkers H, Moore K, Moreno E, Mummery CL, Robin C, Suda T, Van Pel M, Vanden Brink G, Zwaginga JJ, Fibbe WE. Staal FJ, et al. Among authors: zwaginga jj. Leukemia. 2011 Jul;25(7):1095-102. doi: 10.1038/leu.2011.52. Epub 2011 Apr 29. Leukemia. 2011. PMID: 21527933 Review.
Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II study.
Roex MCJ, van Balen P, Germeroth L, Hageman L, van Egmond E, Veld SAJ, Hoogstraten C, van Liempt E, Zwaginga JJ, de Wreede LC, Meij P, Vossen ACTM, Danhof S, Einsele H, Schaafsma MR, Veelken H, Halkes CJM, Jedema I, Falkenburg JHF. Roex MCJ, et al. Among authors: zwaginga jj. Leukemia. 2020 Mar;34(3):831-844. doi: 10.1038/s41375-019-0600-z. Epub 2019 Oct 17. Leukemia. 2020. PMID: 31624377 Clinical Trial.
What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
Ten Ham RMT, Hövels AM, Hoekman J, Frederix GWJ, Leufkens HGM, Klungel OH, Jedema I, Veld SAJ, Nikolic T, Van Pel M, Zwaginga JJ, Lin F, de Goede AL, Schreibelt G, Budde S, de Vries IJM, Wilkie GM, Dolstra H, Ovelgönne H, Meij P, Mountford JC, Turner ML, Hoefnagel MHN. Ten Ham RMT, et al. Among authors: zwaginga jj. Cytotherapy. 2020 Jul;22(7):388-397. doi: 10.1016/j.jcyt.2020.03.432. Epub 2020 May 12. Cytotherapy. 2020. PMID: 32414635 Free article.
245 results